The landscape of preclinical drug discovery is undergoing a seismic shift. Once considered a niche technological curiosity, digital pathology has evolved into a cornerstone of modern laboratory science. Spurred by the logistical constraints of the COVID-19 pandemic—which forced pathologists to trade physical microscopes for high-resolution digital screens—the field has matured into a sophisticated engine for data extraction. Today, researchers are doing more than just viewing images remotely; they are mining vast archives of digitized tissue to uncover molecular insights that were previously locked away in paraffin blocks, effectively creating a path to reduce the reliance on animal testing.
The Digital Transformation: From Static Reports to Dynamic Data
Historically, the pathology workflow was a one-way street. A pathologist would examine a glass slide, dictate a brief report, and the physical specimen would be consigned to a storage facility, essentially becoming a “dead” asset.
“Before, the pathology endpoint was just a report,” explains Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories. “Now, you have the digitized slide, which is essentially a collection of pixels waiting to be interrogated.”
By transitioning from glass to digital, laboratories are transforming static observations into rich, machine-readable datasets. These images can be paired with existing pathology reports and molecular measurements to train artificial intelligence (AI) models. These models are capable of identifying subtle, complex patterns associated with specific biological changes—patterns often invisible to the human eye. This shift turns a single tissue slide into a versatile data source capable of answering questions that were not even on the table when the original study was conducted.
A Chronology of Innovation and Regulatory Evolution
The movement toward modernizing preclinical research is not happening in a vacuum; it is supported by a clear regulatory and technological timeline that has accelerated in recent years.
- 2020–2021 (The Pandemic Catalyst): Global lockdowns forced the mass adoption of digital pathology workflows. This necessity proved that remote, digital analysis was not only viable but highly efficient, laying the infrastructure for subsequent data-mining efforts.
- 2022 (The FDA Modernization Act 2.0): This landmark legislation signaled a major turning point, legally allowing for non-animal methods to support applications for human clinical trials.
- 2024 (Strategic Initiatives): Charles River Laboratories launched its "Alternative Methods Advancement Project," signaling a corporate-wide commitment to integrating advanced methodologies into standard toxicology workflows.
- 2025 (Refining the Standard): The OECD released critical guidance on sample collection for omics analysis, providing a framework for how archived tissue could be leveraged for gene expression and protein studies, provided proper storage protocols were followed.
- 2026 (The Roadmap to Change): The FDA published a comprehensive roadmap aimed at phasing out traditional animal testing in preclinical safety studies. The agency’s stated goal is to transition from animal-centric models to "New Approach Methodologies" (NAMs) over the next three to five years, starting with monoclonal antibodies and expanding to broader chemical entities.
Maximizing the Value of Every Specimen
The primary objective of these modern initiatives is to extract more utility from the animals already involved in studies. In traditional toxicology, researchers often use large, concurrent control groups to establish baselines. By implementing "virtual control groups"—utilizing high-quality historical data matched to current study conditions—laboratories can significantly reduce the number of animals required for each study.
“Control animals are always a big fraction of every study,” Dr. Zuraw notes. “By generating enough matched, historical data, we can provide virtual controls wherever it is statistically sound to do so, replacing the need for additional live subjects.”
Beyond virtual controls, the preservation of Formalin-Fixed, Paraffin-Embedded (FFPE) tissue blocks represents a gold mine for retrospective research. In the past, if a researcher realized a new, unanswered question about a drug’s mechanism of action after a study concluded, the standard protocol was to initiate a new animal experiment. Today, researchers can return to the archived FFPE blocks, perform molecular testing, and correlate the results with original study findings. This allows scientists to answer complex inquiries without sacrificing a single additional animal.
Technical Breakthroughs: Virtual Staining and AI
The technological frontier is currently dominated by two major advancements: molecular prediction from H&E-stained slides and virtual staining.
Molecular prediction involves using AI to interpret H&E-stained slides to predict molecular markers that previously required costly, time-consuming laboratory tests. As Dr. Zuraw describes it, this is a significant area of development: “You take a digitized H&E image, and without using any other methodology, you apply new computational tools to extract deep biological insights.”
Virtual staining is perhaps even more disruptive. By using software to generate the appearance of a stain on an unstained tissue section, labs are moving toward a future where they can bypass the chemical staining process and, potentially, the glass slides themselves. This technology not only speeds up the workflow but also allows for multiple "stains" to be applied digitally to the same tissue section, offering a level of flexibility that traditional chemistry cannot match.
Implications for Global Research Standards
The transition to these new methods is not without its hurdles. To move from experimental success to industry-wide routine, the field requires a robust culture of "early adopters."
“You still need enough early adopters to generate precedent,” Dr. Zuraw explains. “Those early adopters will embrace the regulatory guidance, figure it out, and troubleshoot the process. Then, others can build on their work without having to reinvent the wheel.”
The implications of this shift are profound:
- Ethical Advancement: Reducing the reliance on animal models aligns with global ethical mandates and the 3Rs (Replacement, Reduction, and Refinement) in animal research.
- Economic Efficiency: By reducing the need for redundant studies and utilizing existing archived samples, pharmaceutical companies can decrease the time and capital invested in early-stage drug development.
- Scientific Precision: Data-driven, digital pathology often yields more reproducible and granular results than manual examination, potentially leading to safer drugs reaching clinical trials faster.
Conclusion: A Snowball Effect
The digital pathology revolution is currently in the midst of a "snowball effect." As laboratories realize that archived samples are not mere waste but valuable, living data repositories, the pressure to adopt digital systems will only increase. By integrating virtual controls, molecular mining of archived tissue, and cutting-edge virtual staining, the scientific community is building a framework where animal studies are the exception, not the rule.
As regulatory agencies like the FDA continue to issue guidance and clear pathways for NAMs, the standard of care in preclinical research will continue to migrate toward a digital-first model. The work currently being pioneered by experts like Dr. Zuraw at Charles River Laboratories is not just about changing how we look at slides; it is about fundamentally redefining the ethics and efficiency of the entire drug discovery pipeline. In the coming years, the "old" tissue sitting in archive rooms may well hold the key to the next generation of life-saving medical breakthroughs, proving that the future of discovery is deeply rooted in the data of our past.
About the Author
